Found: 991
Select item for more details and to access through your institution.
Puerarin Alleviates Lipopolysaccharide-Induced Myocardial Fibrosis by Inhibiting PARP-1 to Prevent HMGB1-Mediated TLR4-NF-κB Signaling Pathway.
- Published in:
- Cardiovascular Toxicology, 2020, v. 20, n. 5, p. 482, doi. 10.1007/s12012-020-09571-9
- By:
- Publication type:
- Article
A one‐pot radiosynthesis of [<sup>18</sup>F]PARPi.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2020, v. 63, n. 9, p. 419, doi. 10.1002/jlcr.3847
- By:
- Publication type:
- Article
Regulation of radiation‐induced liver damage by modulation of SIRT‐1 activity: In vivo rat model.
- Published in:
- Cell Biochemistry & Function, 2023, v. 41, n. 1, p. 67, doi. 10.1002/cbf.3762
- By:
- Publication type:
- Article
Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides.
- Published in:
- 2021
- By:
- Publication type:
- journal article
PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 9509, doi. 10.1007/s00432-023-04748-5
- By:
- Publication type:
- Article
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 12, p. 3521, doi. 10.1007/s00432-022-04269-7
- By:
- Publication type:
- Article
PARP inhibition in UV-associated angiosarcoma preclinical models.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 9, p. 2579, doi. 10.1007/s00432-021-03678-4
- By:
- Publication type:
- Article
A New Approach for Studying Poly(ADP-Ribose) Polymerase Inhibitors Using Permeabilized Adherent Cells.
- Published in:
- Biochemistry (00062979), 2024, v. 89, n. 9, p. 1619, doi. 10.1134/S0006297924090086
- By:
- Publication type:
- Article
Study of Interaction of the PARP Family DNA-Dependent Proteins with Nucleosomes Containing DNA Intermediates of the Initial Stages of BER Process.
- Published in:
- Biochemistry (00062979), 2022, v. 87, n. 4, p. 331, doi. 10.1134/S0006297922040034
- By:
- Publication type:
- Article
Analysis of Potential Poly (ADP-Ribose) Polymerase 2 (PARP2) Inhibitor in Nyale Worm (Eunice sp.) Extract for Ovarian Cancer: An In Silico Approach.
- Published in:
- Tropical Journal of Natural Product Research, 2022, v. 6, n. 6, p. 915, doi. 10.26538/tjnpr/v6i6.16
- By:
- Publication type:
- Article
PARP inhibitors bounce back.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 10, p. 725, doi. 10.1038/nrd4147
- By:
- Publication type:
- Article
Anticancer drugs: Expanding the horizons of PARP inhibitors.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
- Published in:
- Nature Reviews Drug Discovery, 2005, v. 4, n. 5, p. 421, doi. 10.1038/nrd1718
- By:
- Publication type:
- Article
Olaparib, a PARP Inhibitor, Prolongs Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 5, p. 1
- By:
- Publication type:
- Article
Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 3, p. 30
- By:
- Publication type:
- Article
Impact of COVID-19 on Telehealth.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 3, p. 1
- By:
- Publication type:
- Article
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer "Graduates" to Phase 3 Study.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 3, p. 1
- By:
- Publication type:
- Article
Early Detection of Cancer Feasible with Blood-Based Tests.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 3, p. 1
- By:
- Publication type:
- Article
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 3, p. 1
- By:
- Publication type:
- Article
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 6, p. 1
- By:
- Publication type:
- Article
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status.
- Published in:
- Oncology Practice Management, 2021, p. 14
- By:
- Publication type:
- Article
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer.
- Published in:
- 2019
- By:
- Publication type:
- Proceeding
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 32
- By:
- Publication type:
- Article
TFEB ameliorates DEHP‐induced neurotoxicity by activating GAL3/TRIM16 axis dependent lysophagy and alleviating lysosomal dysfunction.
- Published in:
- Environmental Toxicology, 2024, v. 39, n. 7, p. 3779, doi. 10.1002/tox.24221
- By:
- Publication type:
- Article
Polystyrene microplastics mediate cell cycle arrest, apoptosis, and autophagy in the G2/M phase through ROS in grass carp kidney cells.
- Published in:
- Environmental Toxicology, 2024, v. 39, n. 4, p. 1923, doi. 10.1002/tox.24068
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- 2023
- Publication type:
- Correction Notice
Methylmercury induced apoptosis of human neuroblastoma cells through the reactive oxygen species mediated caspase and poly ADP‐ribose polymerase/apoptosis‐inducing factor dependent pathways.
- Published in:
- Environmental Toxicology, 2022, v. 37, n. 8, p. 1891, doi. 10.1002/tox.23535
- By:
- Publication type:
- Article
Protective effect of Diosmin against benzo(a)pyrene‐induced lung injury in Swiss Albino Mice.
- Published in:
- Environmental Toxicology, 2020, v. 35, n. 7, p. 747, doi. 10.1002/tox.22909
- By:
- Publication type:
- Article
Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-κB nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
- Published in:
- Neurological Sciences, 2013, v. 34, n. 12, p. 2101, doi. 10.1007/s10072-013-1344-6
- By:
- Publication type:
- Article
Association of poly(ADP-ribose) polymerase-1 polymorphism with Tourette syndrome.
- Published in:
- Neurological Sciences, 2013, v. 34, n. 11, p. 1911, doi. 10.1007/s10072-013-1405-x
- By:
- Publication type:
- Article
miR-155-5p 增强卵巢癌细胞 UWB1.289 对 PARP 抑制剂的敏感性.
- Published in:
- Progress in Modern Biomedicine, 2022, v. 22, n. 18, p. 3420, doi. 10.13241/j.cnki.pmb.2022.18.004
- By:
- Publication type:
- Article
氟苯达唑对人急性髓系白血病 HL-60 细胞的增殖抑制作用研究.
- Published in:
- Progress in Modern Biomedicine, 2020, v. 20, n. 4, p. 648, doi. 10.13241/j.cnki.pmb.2020.04.010
- By:
- Publication type:
- Article
MEDPULSE: Taking the Pulse of the World.
- Published in:
- Meducator, 2019, n. 36, p. 2
- By:
- Publication type:
- Article
O3‐3: miR‐21 regulates the proliferation and apoptosis of human bronchial epithelial cells by targeting PARP‐1.
- Published in:
- Respirology, 2021, v. 26, p. 10, doi. 10.1111/resp.14149_15
- Publication type:
- Article
O3‐3: miR‐21 regulates the proliferation and apoptosis of human bronchial epithelial cells by targeting PARP‐1.
- Published in:
- Respirology, 2021, v. 26, p. 10, doi. 10.1111/resp.14149_15
- Publication type:
- Article
[<sup>18</sup>F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-17460-0
- By:
- Publication type:
- Article
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16623-3
- By:
- Publication type:
- Article
Evaluation of phototoxicity induced by the anticancer drug rucaparib.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07319-9
- By:
- Publication type:
- Article
Harnessing Synthetic Lethal Interactions for Personalized Medicine.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 1, p. 98, doi. 10.3390/jpm12010098
- By:
- Publication type:
- Article
Biomarkers for Homologous Recombination Deficiency in Cancer.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 7, p. 612, doi. 10.3390/jpm11070612
- By:
- Publication type:
- Article
Human PARP1 substrates and regulators of its catalytic activity: An updated overview.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1137151
- By:
- Publication type:
- Article
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.997760
- By:
- Publication type:
- Article
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2022.979873
- By:
- Publication type:
- Article
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1078303
- By:
- Publication type:
- Article
Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1026306
- By:
- Publication type:
- Article
A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.971369
- By:
- Publication type:
- Article
Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.965244
- By:
- Publication type:
- Article
Current landscape of personalized clinical treatments for triple-negative breast cancer.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.977660
- By:
- Publication type:
- Article
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.967633
- By:
- Publication type:
- Article
Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.968060
- By:
- Publication type:
- Article